Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Neutropenia. Found 8 abstracts

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Plimack ER, Desai JR, Issa JP, Jelinek J, Sharma P, Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu WJ. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: Impact on DNA methylation and lymphocyte populations. Investigational New Drugs. 2014 Oct;32(5):969-75.   PMCID: 4171200
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
Held-Warmkessel J. Taming three high-risk chemotherapy complications. Nursing. 2011 Nov;41(11):30-7.   PMCID: not NIH funded
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Padilla G, Ropka ME. Quality of life and chemotherapy-induced neutropenia. Cancer nursing. 2005 Jan;28(3):167-71.
Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs. 2001 Jan;19(1):89-92.
Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol. 2001 Feb 15;19(4):1183-94.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Neutropenia

Neutropenia chemically induced adverse effects Male Female Aged drug therapy administration & dosage therapeutic use Adult Middle Aged adverse Antineoplastic Combined Chemotherapy Protocols Treatment Outcome effects pathology mortality blood Drug Administration Schedule immunology 80 and over Aged Paclitaxel analogs & therapy analogs & derivatives Carboplatin Human Neoplasm Staging Antineoplastic Agents US Gov't Support-PHS Kaplan-Meier Estimate derivatives Middle Age quality of life Neoplasms Bevacizumab prevention & Nursing Methodology Research Renal Cell Carcinoma Carboxymethylcellulose Combination Drug Therapy Multicenter Studies Kidney Neoplasms Antineoplastic Antimetabolites Nursing Assessment Quality of life non-squamous Recombinant Proteins Neoplasm Drug Resistance antineoplastic agent Intestinal Diseases Leukocyte Count non-small-cell lung cancer bevacizumab Androgen Antagonists Poly I-C radiotherapy Lymphoma Stomatitis Lung Neoplasms metabolism Topotecan neutropenia Adjuvant Chemotherapy Non-US Gov't Support Cancer Melanoma Maximum Tolerated Dose DNA Methylation Fever drug Interferon-alpha epidemiology Survival Analysis pharmacology Monoclonal Antibodies-Humanized CA-19-9 Antigen Interferon Inducers pharmacokinetics Conformal Radiotherapy surgery Chemotherapy Biological Tumor Markers Disease-Free Survival Polylysine Prostate-Specific Antigen Kidney Diseases Local Neoplasm Recurrence Axitinib Deoxycytidine Vomiting Azacitidine axitinib Non-Small-Cell Lung Carcinoma Nausea Adjuvant Radiotherapy Proportional Hazards Models Hematopoietic Stem Cell Transplantation Pancreatic Neoplasms Taxoids Hospitalization control T-Lymphocyte Subsets Prostatic Neoplasms chemotherapy Follow-Up Studies Thrombocytopenia Polyethylene Glycols Imidazoles Indazoles
Last updated on Monday, August 10, 2020